The Never Too Young Coalition research goals are to look at the causes associated with a rise in young-onset colon cancer as well as the biological distinction in tumors of those under age 50 compared to those over age 50.
Incidence and death rates of colon cancer have declined in those 50 and above. However, for individuals below age 50, colon cancer is on the rise. Unfortunately, we lack the understanding of why but are committed to supporting research that helps us gain a better understanding so that people can be diagnosed in their earliest most treatable and curable stages.
This is why we formed a partnership with the American Association for Cancer Research (AACR) to fund research that unlocks the answers to this question.
AACR Grant Awards
On April 19, at the American Association for Cancer Research’s Annual Grant Awards Dinner, the Coalition awarded two $50,000 research grants to the following individuals:
- Tatianna C. Larman, MD; Johns Hopkins University; Exploiting a common metabolic susceptibility in early onset sporadic CRC
- Sarah B. Stringfield, MD; University of California, San Diego; Young Onset Colorectal Cancer- A virally mediated process?
Funding New Research in Under 50
Christopher Lieu, MD, Committee Chair, University of Colorado
Anne Carlson, Colon Cancer Coalition
Whitney Jones, MD, Colon Cancer Prevention Project
Paul Wise, MD, Washington University School of Medicine
Y. Nancy You, MD, University of Texas MD Anderson Center
Patrick Boland, MD, Roswell Park Cancer Institute
Thomas Weber, MD, Colon Cancer Challenge Foundation
Jason Zell, MD, Chao Family Comprehensive Cancer Center, University of California Irvine
Rachel Lefebvre, PhD, Committee Co-Vice Chair
Virginia Warren, Arizona Department of Health Services
Anjee Davis, MPPA, Fight Colorectal Cancer
Thomas Imperiale, MD, Indiana University School of Medicine
Tom Marsilje, PhD, Committee Co-Vice Chair
Lynch syndrome is a genetic mutation that increases a person’s risk for certain cancers. It is the most common inherited cause of colon cancer. Many individuals with a Lynch mutation develop related cancers at very early ages, much younger than the general population.
What is The HEROIC Registry?
The HEROIC Registry is the first of it’s kind. A patient-centric genetic database that will enable patients to take an active role in furthering research into Lynch Syndrome genetic mutations. The HEROIC Registry allows patients to contribute medical information and their experiences living with Lynch Syndrome and its associated cancers to help researchers develop new treatments, understand the various Lynch genetic mutations, write medical papers and conduct further studies and clinical trials. Your data can shape the types of research studies to be conducted that are most beneficial to you – the patient.
For more information about participating in the HEROIC Registry click below.